Background:

NNC45-0781 is a tissue-selective estrogen partial-agonist.

NNC45-0781 (NNC 45-0781) shows that it is a very promising tissue-selective estrogen agonist. Total serum cholesterol is significantly increased in the vehicle-treated group as compared to the sham animals. All of the animals receiving NNC45-0781 at doses of 10 nmol/g or higher, has significantly lower levels of total serum cholesterol as compared to the vehicle treated group[1].

[1]. Bury PS, et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002 Jan;10(1):125-45.